Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers

被引：0
|
作者：
Y. K. Pithavala
M. Tortorici
M. Toh
M. Garrett
B. Hee
U. Kuruganti
G. Ni
K. J. Klamerus
机构：
[1] La Jolla Laboratories,Pfizer Oncology, Pfizer Global Research and Development
[2] Pfizer Oncology,undefined
[3] Pfizer Ophthalmology,undefined
[4] CK Life Sciences,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2010年 / 65卷
关键词：
Anticancer agents; Pharmacokinetics; Healthy volunteers; Ethnic groups; Plasma drug concentrations; Adverse drug events;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：563 / 570
页数：7
相关论文
共 50 条
  • [1] Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers
    Pithavala, Y. K.
    Tortorici, M.
    Toh, M.
    Garrett, M.
    Hee, B.
    Kuruganti, U.
    Ni, G.
    Klamerus, K. J.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 65 (03) : 563 - 570
  • [2] Effect of Rifampin on the plasma pharmacokinetics of Axitinib (AG-013736) in Caucasian and Japanese healthy volunteers
    Pithavala, Yazdi
    Tortorici, Michael
    Toh, Melvin
    Garrett, May
    Hee, Brian
    Kuruganti, Uma
    Ni, Grace
    Klamerus, Karen
    CANCER RESEARCH, 2008, 68 (09)
  • [3] Effect of food on the pharmacokinetics of Axitinib (AG-013736) in healthy volunteers
    Pithavala, Yazdi
    Toh, Melvin
    Mount, Janessa
    Garrett, May
    Hee, Brian
    Selaru, Paulina
    Klamerus, Karen
    CANCER RESEARCH, 2008, 68 (09)
  • [4] Effect of Ketoconazole on the plasma pharmacokinetics of Axitinib (AG-013736) in healthy volunteers
    Pithavala, Yazdi
    Klamerus, Karen
    Garrett, May
    Hee, Brian
    Mount, Janessa
    Selaru, Paulina
    Sarapa, Nenad
    CANCER RESEARCH, 2008, 68 (09)
  • [5] An open-label phase 1 study to evaluate the pharmacokinetics of axitinib (AG-013736) in healthy Chinese volunteers
    Chen, Ying
    Jiang, Ji
    Zhang, Jianyan
    Tortorici, Michael
    Pithavala, Yazdi K.
    Lu, Lei
    Ni, Grace
    Hu, Pei
    CANCER RESEARCH, 2010, 70
  • [6] Effect of axitinib (AG-013736) concentration on QT interval after administration alone and in combination with ketoconazole in healthy volunteers.
    Houk, B. E.
    Sarapa, N.
    Pithavala, Y. K.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S53 - S53
  • [7] INFLUENCE OF SELECTED DEMOGRAPHIC AND CLINICAL FACTORS ON THE PHARMACOKINETICS (PK) AND EFFICACY OF AXITINIB (AG-013736; AG) IN HEALTHY VOLUNTEERS (HVS) AND METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS
    Garrett, M.
    Pithavala, Y. K.
    Rini, B. I.
    Rixe, O.
    Bukowski, R. M.
    Kim, S.
    Amantea, M. A.
    Houk, B. E.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 : S43 - S43
  • [8] COMPARISON OF AXITINIB ( AG-013736; AG) PHARMACOKINETICS ( PK) IN HEALTHY VOLUNTEERS ( HVS; RICH DATA) AND PATIENTS ( PTS; SPARSE DATA) USING POPULATION PK ANALYSIS.
    Tortorici, M. A.
    Fruehauf, J. P.
    Schiller, J. H.
    Cohen, E. E.
    Niethammer, A.
    Pithavala, Y. K.
    Garrett, M.
    Ruiz-Garcia, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 : S75 - S75
  • [9] Effect of axitinib (AG-013736) on thyroid function and biomarkers: Results from phase studies in Japanese patients
    Fujiwara, Yutaka
    Kiyota, Naomi
    Chayahara, Naoko
    Suzuki, Akiyuki
    Umeyama, Yoshiko
    Mukohara, Toru
    Minami, Hironobu
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [10] Development of an efficient Pd catalyzed process for Axitinib (AG-013736)
    Srirangam, Jay K.
    Yu, Shu
    Singer, Rob
    Flahive, Erik
    Sach, Neal
    Tian, Qingping
    Babu, Srin
    Saenz, James
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 243
12345